Adamed Group sets up offices in the Czech Republic and Slovakia

The company’s local branch offices – Adamed Czech Republic and Adamed Slovakia – were thus launched. The group will be on the lookout for more potential acquisitions in other European markets in future.

“The company’s foray into the Czech and Slovak markets results from its long-term globalization strategy, which we see as a chance for Adamed Group’s dynamic development. For years, we have been consistently strengthening our position in foreign markets, as reflected by the recent addition of two new local operators to the existing structure which includes entities from Spain, Russia, Ukraine and Kazakhstan. In the new markets, we will first focus on prescription drugs, but in the near future we will also launch OTCs and dietary supplements,” says Michał Wieczorek, Commercial Director at Adamed Group.

In 2016, the Group took over Genericon and Interchemia – companies which operated in both the Czech Republic and Slovakia. However, Michał Wieczorek underscores that the company is prepared to make more interesting local acquisitions. The goal is to be among the 20 largest pharmaceutical companies in both the Czech Republic and Slovakia.

Business development in Poland’s southern neighbors feeds into a broader international context of the Group’s operations. The company started its exports activity back in 2003 and its products are currently available to patients in Europe, the Middle East, Asia, Latin America and Oceania.